Regulatory T cell activator and use thereof
US-11059888-B2 · Jul 13, 2021 · US
CD226 agonist antibodies
US11440959B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11440959-B2 |
| Application number | US-201916500947-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jul 19, 2019 |
| Priority date | Jul 26, 2018 |
| Publication date | Sep 13, 2022 |
| Grant date | Sep 13, 2022 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.
First claim
Opening claim text (preview).
I claim: 1. An anti-human CD226 antibody, comprising an HCDR1 having the amino acid sequence of SEQ ID NO: 1, an HCDR2 having the amino acid sequence of SEQ ID NO: 2, an HCDR3 having the amino acid sequence of SEQ ID NO: 3, an LCDR1 having the amino acid sequence of SEQ ID NO: 4, an LCDR2 having the amino acid sequence of SEQ ID NO: 5, and an LCDR3 having the amino acid sequence of SEQ ID NO: 6. 2. The anti-human CD226 antibody of claim 1 , comprising an HCVR having the amino acid sequence of SEQ ID NO: 7 and an LCVR having the amino acid sequence of SEQ ID NO: 8. 3. The anti-human CD226 antibody of claim 1 , comprising an HC having the amino acid sequence of SEQ ID NO: 9, and an LC having the amino acid sequence of SEQ ID NO: 10. 4. The anti-human CD226 antibody of claim 1 , consisting of two HCs having the amino acid sequence of SEQ ID NO: 9, and two LCs having the amino acid sequence of SEQ ID NO: 10. 5. A pharmaceutical composition, comprising the anti-human CD226 antibody of 3, and an acceptable carrier, diluent, or excipient. 6. A DNA molecule comprising a polynucleotide having the sequence of SEQ ID NO: 11, SEQ ID NO: 12, or SEQ ID NOS: 11 and 12. 7. A method of treating a solid tumor cancer, comprising administering to a patient in need thereof, an effective amount of the anti-human CD226 antibody of 3, wherein the solid tumor cancer is bladder cancer, breast cancer, cervical cancer, colorectal cancer, endometrial cancer, head and neck cancer, liver cancer, lung cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, renal cancer, soft tissue sarcoma, gastric cancer, testicular cancer, thyroid cancer, uterine cancer or urothelial cancer.
Assignees
Inventors
Classifications
Complementarity determining region [CDR] · CPC title
comprising antibodies · CPC title
Agonist effect on antigen · CPC title
- C07K16/2803Primary
against the immunoglobulin superfamily · CPC title
Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US11440959B2 cover?
- The present invention relates to anti-human CD226 agonist antibodies, which can be useful for treating solid tumor cancers.
- Who is the assignee on this patent?
- Lilly Co Eli
- What technology area does this patent fall under?
- Primary CPC classification C07K16/2803. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 1 related publication on this page (citations in our corpus or others sharing the same primary CPC).